Compatibility and activity of enoxaparin sodium in 0.9% sodium chloride injection for 48 hours

American Journal of Health-System Pharmacy

Volumn 53, Issue 2, 1996, Pages 167-169

  Mewborn, Amy L ^a,b   Kessler, John M ^c   Joyner, Kelly A ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c U of WI School of Pharmacy   (United States)

^d DUMC   (United States)

Author keywords

Additives; Anticoagulants; Containers; Diluents; Enoxaparin sodium; Incompatibilities; Polyvinyl chloride; Sodium chloride; Stability; Storage

Indexed keywords

ENOXAPARIN; POLYVINYLCHLORIDE; SODIUM CHLORIDE;

ARTICLE; COLOR; DRUG ACTIVITY; DRUG DETERMINATION; DRUG INCOMPATIBILITY; DRUG STABILITY; DRUG STORAGE; GAS; PRECIPITATION; PRIORITY JOURNAL;

EID: 0030070596     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.2.167     Document Type: Article

References (7)

1. Lovenox package insert. Collegeville, PA: Rhone-Poulenc Rorer Pharmaceuticals; 1993 Mar.
2. Samama CM, Barre E, Combe S et al. A pilot study on the use of a low molecular weight heparin (enoxaparin) in arterial reconstructive surgery. Semin Thromb Hemost. 1991; 17:367-9.
3. Simonneau G, Charbonnier B, Decousus H et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med. 1993; 153:1541-6.
4. Turpie AGG. Efficacy of a postoperative regimen of enoxaparin in deep vein thrombosis prophylaxis. Am J Surg. 1991; 161:532-6.
5. Vitoux JF, Mathieu JF, Roncato M et al. Heparin-associated thrombocytopenia treatment with low molecular weight heparin. Thromb Haemost. 1986; 55:37-8.
6. Toulon P, Vitoux JF, Leroy C et al. Circulating activities during constant infusion of heparin or a low molecular weight derivative (enoxaparine): failure to demonstrate any circadian variations. Thromb Haemost. 1987; 58:1068-72.
7. Bara L, Billaud E, Gramond G et al. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res. 1985; 39:631-6.